As the results of the PAPILLON trial revealed, the PFS of amivantamab–chemotherapy was longer than chemotherapy alone in first-line therapy for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations. Here, EGFR is linked to non-small cell lung carcinoma.